Matthew D. Surman

Matthew D. Surman


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMichael E Stokes
Michael E Stokes
MSMatthew D. Surman
Matthew D. Surman
VCVeronica Calvo
Veronica Calvo
DSDavid Surguladze
David Surguladze
ALAn-Hu Li
An-Hu Li
MMMark J. Mulvihill
Mark J. Mulvihill
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) responsible for regulating protein synthesis and alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway biology in vitro and in vivo, with pharmacokinetics suitable for once-a-day oral dosing in mice.